No abstract

dex scores have been slightly increased from 0.94 to 0.96 during 2007-2010. Male adults had higher EQ-5D index scores than female (0.96 vs. 0.92). Elderly (ageՆ60) had significantly lower EQ-5D index scores (score ranges: 0.02 to 0.11) than young adult (ageϭ19-29) after adjusting for other variables. EQ-5D index scores were significantly reduced by stroke (reduced by -0.10), arthritis (reduced by -0.05), cardiovascular disease (reduced by -0.04), and diabetes (reduced by -0.02). CONCLUSIONS: QOL in South Korean adults was significantly reduced by chronic diseases and age. Despite national efforts to detect and treat chronic diseases at early stage of disease, significant reduction in QOL due to chronic diseases still exist. It is emphasized the need for implementation of effective public health programs for decreased prevalence of chronic diseases.

The aim of this study was to assess the lifetime economic benefits of assisted reproduction in Spain by calculating the return on this investment. We developed a generational accounting model that simulates the flow of taxes paid by the individual, minus direct government transfers received over the individual’s lifetime. The difference between discounted transfers and taxes minus the cost of either IVF or artificial insemination (AI) equals the net fiscal contribution (NFC) of a child conceived through assisted reproduction. We conducted sensitivity analysis to test the robustness of our results under various macroeconomic scenarios. A child conceived through assisted reproduction would contribute €370,482 in net taxes to the Spanish Treasury and would receive €275,972 in transfers over their lifetime. Taking into account that only 75% of assisted reproduction pregnancies are successful, the NFC was estimated at €66,709 for IVF-conceived children and €67,253 for AI-conceived children. The return on investment for each euro invested was €15.98 for IVF and €18.53 for AI. The long-term NFC of a child conceived through assisted reproduction could range from €466,379 to €-9,529 (IVF) and from €466,923 to €-8,985 (AI). The return on investment would vary between €-2.28 and €111.75 (IVF), and €-2.48 and €128.66 (AI) for each euro invested. The break-even point at which the financial position would begin to favour the Spanish Treasury ranges between 29 and 41 years of age. Investment in assisted reproductive techniques may lead to positive discounted future fiscal revenue, notwithstanding its beneficial psychological effect for infertile couples in Spain.

A339pregnancy outcomes. Methods: To determine whether additional clinical tests, advice, planning, management or pregnancy follow-up were recommended for obese women during pregnancy,Clinical Practice Guidelines (CPGs) were collated from across the Endocrinology and Obstetrics National Societies websites of the 9 European countries participating in the FP7 DALI study

DT nº 01/2017 »»» Tabla 1. Comparación de definiciones de biosimilares en el mundo Nomenclatura Regulador Definición Similar biological medicinal products UE / EMA (2006) Medicamentos biológico que se desarrolla para que sea similar a un medicamento biológico exixtente. Cuando se aprueba, se ha demostrado que su variabilidad y las duiferencias entre este y su medicamento de referencia no afectan la seguridad o eficiencia. Similar biotherapeutic products WHO (2009) Producto bioterapéutico que es similar en términos de calidad, seguridad y eficacia a un producto bioterapéutico de referencia autorizado previamente. Biothechnological drug products Japón / PMDA (2009) Producto farmacológico biotecnológico, desarrollado por una empresa difeente, que es comparable a un producto derivado de la biotecnología de una empresa innovadora (producto de referencia). Subsequent entry products Health Canada (2010) Es un fármaco biológico que entra en el mercado después de una versión previamente autorizada en Canada y con similaridad demostrada a un fármaco biológico de referencia. Follow-on products EEUU /FDA (2012) Producto biológico qye es muy similar a un produzcto biológico de referencia con autorización de EE.UU., independientemente de las diferencias menores entre el producto biológico y el producto de referencia en términos de seguridad, pureza y concentración del producto. Biosimilar medicines Australia / TGA (2013) Un medicamento biosimilar es una versión de una medicina biológica y aregistrada (el medicamento de referencia). Tanto el biosimilar como su medicamento de referencia tendrán las siguientes características similares (demostradas mediante estudios de comparabilidad completos): Físicoquímicas, biológicas, inmunológicas, eficacia y seguridad.